ATTD Yearbook & More
This category provides fast access to the ATTD Yearbook and useful specialist resources, including media, expert opinion articles, and a range of medical resources.
In February 2020, organizers of the Advanced Technologies & Treatments for Diabetes (ATTD) Annual Conference convened an international panel of healthcare professionals, researchers, patient advocates, and industry representatives to review the status of digital diabetes technologies, characterize deficits in current technologies, and identify issues for consideration. Since that meeting, the importance of using telehealth and digital diabetes technologies has been demonstrated amid the global COVID-19 pandemic. This article summarizes the panel’s discussion of the opportunities, obstacles and requisites for advancing use of these technologies as a standard of care for the management of diabetes.
Diabetes Technol Ther 2020 Sep 9. doi: 10.1089/dia.2020.0375. Online ahead of print.
Access the full article on the Diabetes Technology & Therapeutics website: https://www.liebertpub.com/doi/10.1089/dia.2020.0375
ATTD International Consensus Meetings on Time in Range (TIR) – BERLIN 2019
Continuous glucose monitoring (CGM) is now increasingly used in routine clinical practice and is gaining appreciation from its users. With its broad use, novel parameters for a better definition of targets for successful metabolic control are available but a consensus between health care professionals and PwD on these parameters is lacking.
In February 2019 the ATTD convened a consensus meeting with an international panel of 30 key opinion leaders in order to establish appropriate settings for a broad and clinically viable consensus on Time in Range (TIR). These are now summarized in a publication in Diabetes Care.
Diabetes Care 2019; 42:1593-1603
Access the full article on the Diabetes Care website
ATTD International Consensus on the use of SGLT1&2 inhibitors in treating T1D – ORLANDO 2018
Recent study results show a significant clinical benefit of adjunct therapy with SGLT1&2 inhibitors in addition to insulin in type 1 diabetes. However, this is accompanied by slightly higher DKA rates than placebo in several studies.
In June 2018, the ATTD convened a consensus meeting with an international panel of 30 physicians and researchers with expertise in using SGLT-inhibitor therapy in order to find ways to mitigate DKA and euDKA risk. These are now summarized in a publication in Diabetes Care.
Diabetes Care 2019; 42:1147-1154
Access the full article on the Diabetes Care website
"Periodically,a new idea, method, or tool leads to a turning point in the Management of diabetes. We believe such a moment is now upon us, brought by the
development of reliable devices for continuous glucose monitoring (CGM)."
- Editorial by Matthew C. Riddle, Hertzel C. Gerstein, and William T. Cefalu, Diabetes Care 2017;40:1611–1613.At ATTD 2017, an international panel of physicians, researchers, and individuals with diabetes came together for a consensus meeting and addressed the issues around continuous glucose monitoring (CGM).
Even though CGM moves beyond HbA1c measurement, there are issues such as the lack of standardized metrics for analyzing CGM data, and no clear criteria for matching patients to most appropriate glucose monitoring methodologies.
Consensus recommendations and the current understanding of how CGM results can affect outcomes are now summarizes in a publication in Diabetes Care.
View Summary:
Access the ATTD International Consensus on the Use of Continuous Glucose Monitoring.pdf (PDF)
Access the full article on the Diabetes Care website
Access the ATTD International Consensus on the Use of Continuous Glucose Monitoring.pdf (PDF)
Access the full article on the Diabetes Care website
ATTD CONSENSUS STATEMENT on the use of Continuous Glucose Monitoring (CGM) in the Pediatric age-group – PARIS 2011
The use of real-time continuous glucose monitoring (CGM) providing continuous glucose measurements became popular and helped PwD to optimize glycemic control and reduce the risk of hypoglycemia. Yet, the benefits of the current CGM systems have been more challenging to demonstrate, especially in pediatric patients.
In order to address these issues, ATTD, together with the European Society for Pediatric Endocrinology (ESPE), the Pediatric Endocrine Society (PES), and the International Society for Pediatric and Adolescent Diabetes (ISPAD) convened a panel of expert physicians for a consensus conference.
Pediatric Diabetes 2012; 13:215-228
Access the full article on the Pediatric Diabetes website
Consensus Statement on the use of insulin pump therapy in the pediatric age group – BERLIN 2006
The Consensus meeting held in Berlin in April 2006 was organized by the Loop Club, which preceded the ATTD, together with European Society for Pediatric Endocrinology (ESPE), the Lawson Wilkins Pediatric Endocrine Society (LWPES), and the International Society for Pediatric and Adolescent Diabetes (ISPAD) and endorsed by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
A panel of expert physicians discussed the advantages of the use of pump therapy in the pediatric age group.
Diabetes Care 2007; 30:1653-1662
Access the full article on the Diabetes Care website
Diabetes Care is a journal for the
health care practitioner that is intended to increase knowledge,
stimulate research, and promote better management of people with
diabetes.
The journal also publishes ADA statements, consensus
reports, clinically relevant review articles, letters to the editor,
and health/medical news or points of view. Topics covered are of
interest to clinically oriented physicians, researchers,
epidemiologists, psychologists, diabetes educators, and other health
professionals.
Click here to access the Diabetes Care publication online
Diabetes publishes original research about the physiology and pathophysiology of diabetes mellitus. Submitted manuscripts can report any aspect of laboratory, animal, or human research. Emphasis is on investigative reports focusing on areas such as the pathogenesis of diabetes and its complications, normal and pathologic pancreatic islet function and intermediary metabolism, pharmacological mechanisms of drug and hormone action, and biochemical and molecular aspects of normal and abnormal biological processes. Studies in the areas of diabetes education or the application of accepted therapeutic and diagnostic approaches to patients with diabetes mellitus are not published.
Click here to access the publication online
JCEM is the world’s leading peer-reviewed journal for endocrine clinical research and clinical practice. Article types include: original research, reviews, case reports, commentaries, and consensus statements.
Click here to access the publication online
The Journal of Diabetes Science and Technology (JDST) is a bi-monthly, peer-reviewed scientific journal published by the Diabetes Technology Society.
JDST covers scientific and clinical aspects of diabetes technology including glucose monitoring, insulin and metabolic peptide delivery, the artificial pancreas, digital health, precision medicine, social media, cybersecurity, software for modeling, physiologic monitoring, technology for managing obesity, and diagnostic tests of glycation. The journal also covers the development and use of mobile applications and wireless communication, as well as bioengineered tools such as MEMS, new biomaterials, and nanotechnology to develop new sensors. Articles in JDST cover both basic research and clinical applications of technologies being developed to help people with diabetes.
Click here to access the publication online
Diabetes, Obesity and Metabolism: A Journal of Pharmacology and Therapeutics is the only interdisciplinary journal for high-quality research and reviews in the areas of diabetes, obesity and metabolism. It focuses on clinical and experimental pharmacology and therapeutics in any aspect of metabolic and endocrine disease, either in humans or animal and cellular systems.
Diabetes Technology & Therapeutics is the only peer-reviewed journal providing healthcare professionals with information on new devices, drugs, drug delivery systems, and software for managing patients with diabetes. This leading international journal delivers practical information and comprehensive coverage of cutting-edge technologies and therapeutics in the field, and highlights new pharmacological and device developments to optimize patient care.
Diabetes Technology & Therapeutics is under the editorial leadership of Editor-in-Chief Satish K. Garg, MD, University of Colorado Denver, Barbara Davis Center for Childhood Diabetes; Senior Editors Jay S. Skyler, MD, MACP, University of Miami Miller School of Medicine, and Irl B. Hirsch, MD, University of Washington Medical Center–Roosevelt; and other leading investigators.
Click here to access the online publication
touchENDOCRINOLOGY.com
is an independent information resource designed to support physicians,
clinicians and related healthcare professionals in continuously
developing their knowledge, effectiveness and productivity, with open
access articles and multimedia content.
European Endocrinology is a peer-reviewed, open access, bi-annual journal comprising review articles, case reports, practice guides, theoretical discussions, and original research. It features balanced and comprehensive articles written by leading authorities, addressing the most important and salient developments in the field of endocrinology.
Click here to access this resource online
The mission of Hormone Research in Paediatrics is to improve the care of children with endocrine disorders by promoting basic and clinical knowledge. The journal facilitates the dissemination of information through original papers, mini-reviews, clinical guidelines and papers on novel insights from clinical practice.
Click here to access this publication online.
Data at the frontiers of diabetes research are collected, systematically organized, and critically evaluated by volumes in this series. Contents are based on recent findings published in the medical literature and reflect the most advanced achievements in current clinical and experimental research on diabetes and allied disorders. By giving these data coherent organization and critical interpretation, the editor and authors of ‘Frontiers in Diabetes’ perform a major service for all scientists conducting experimental or clinical work in the field.
Click here to view the publication online.
The Lancet journals publish original research, reviews, and topical Comment about diabetes,
endocrinology, and metabolism. Topics considered by the journal
include—but are not limited to—diabetes, obesity, nutrition and
metabolism, osteoporosis, adrenal disorders, bone metabolism, growth
disorders, lipid disorders, neuroendocrinology, paediatric
endocrinology, pituitary disorders, reproductive endocrinology, and
thyroid disorders.
Click here to access the publication.
Nature Medicine publishes research that addresses the needs and goals of contemporary medicine. Original research ranges from new concepts in human biology and disease pathogenesis to robust preclinical bases for new therapeutic modalities and drug development to all phases of clinical work, as well as innovative technologies aimed at improving human health.
Nature Medicine also publishes Reviews, Perspectives and other content commissioned from leading scientists in their fields to provide expert and contextualized views of the latest research driving the progress of medicine. The News section is editorially independent and provides topical and timely reporting of upcoming trends affecting medicine, researchers and the general audience.
Click here to access the publication.
Pediatric Diabetes is a bi-monthly journal devoted to disseminating new knowledge relating to the epidemiology, etiology, pathogenesis, management, complications and prevention of diabetes in childhood and adolescence. The aim of the journal is to become the leading vehicle for international dissemination of research and practice relating to diabetes in youth. Papers are considered for publication based on the rigor of scientific approach, novelty, and importance for understanding mechanisms involved in the epidemiology and etiology of this disease, especially its molecular, biochemical and physiological aspects. Work relating to the clinical presentation, course, management and outcome of diabetes, including its physical and emotional sequelae, is considered. In vitro studies using animal or human tissues, whole animal and clinical studies in humans are also considered. The journal reviews full-length papers, preliminary communications with important new information, clinical reports, and reviews of major topics. Invited editorials, commentaries, and perspectives are a regular feature. The editors, based in the USA, Europe, and Australasia, maintain regular communications to assure rapid turnaround time of submitted manuscripts.